• Prescribing Information
  • Medical Information
  • Patient Adherence

    Tools that help patients finish TRUMENBA

    Pfizer TruSupport offers tools that will help your patients stay on track with TRUMENBA, so you can rest assured they’re protected against MenB.

    Your patients value and trust your recommendation. At the time of their first dose, communicate the importance of dose series completion to your patients and their parents and schedule their next dose appointment.

    Email Template

    Provider recommendation has been shown to improve vaccination coverage by as much as 41%​​​​​​​.2

    Email Template

    In a recent study, patients with prescheduled flu vaccination appointments were almost 7 times more likely to get vaccinated.​​​​​​​3

    Email Template

    Postcard reminders

    Reminder Recall programs can help increase awareness to patients who are due a first or subsequent dose of TRUMENBA at an upcoming well visit.

    Patients who receive postcard reminders are 40% more likely to get vaccinated.3

    Talk to a Pfizer Sales Representative for more information.

    Pharmacy locator​​​​​​​

    • Online locator that patients can use to find the nearest pharmacy that vaccinates with TRUMENBA
    • Especially helpful for college students who are unable to return to your practice for their next dose of TRUMENBA
    How to get TRUMENBA

    Contact your Pfizer Sales Representative or call a Vaccine Specialist at 
    1-844-439-2571 to learn more about Pfizer TruSupport.


    References:
    1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
    2. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila). 2013;52(2):162-170.
    3. Chapman GB, Li M, Leventhal H, Leventhal EA. Default clinic appointments promote influenza vaccination uptake without a displacement effect. Behav Sci Policy. 2016;2(2):41-50.

    Support & Order

    • Welcome to TruSupport
    • Ordering & Inventory
    • Coverage & Reimbursement
    • Patient Adherence

    Ordering & Inventory with TruSupport

    Provides multiple convenient options for ordering TRUMENBA​​​​​​

    View the options

    Coverage & Reimbursement with TruSupport

    Streamlines the processes of confirming your patient's coverage for TRUMENBA

    Learn how Pfizer streamlines

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​